Hepatitis C virus and lymphoma

ONCH-1893; No. of Pages 11

ARTICLE IN PRESS

Critical Reviews in Oncology/Hematology xxx (2014) xxx–xxx

Hepatitis C virus and lymphoma Semra Paydas ∗ Cukurova University, Faculty of Medicine, Dept of Oncology, 01330 Adana, Turkey Accepted 14 October 2014

Contents 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11.

Introduction. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . What is the most common extra-hepatic manifestation of HCV? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . What is risk of NHL in cases with HCV? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Which test is more useful to determine the prevalence of HCV in cases with lymphoma? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . What is the route of HCV transmission? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . What is the pathogenetic role of HCV in NHL? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . What is the clinical/pathological/genotypic properties of HCV related NHL? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Anti-viral treatment for HCV associated NHL: when and whom? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Management of DLBCL associated with HCV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Potential benefits/harms of rituximab and anti-viral using in cases with HCV associated NHL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Reviewers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

00 00 00 00 00 00 00 00 00 00 00 00 00

Abstract Hepatitis C virus (HCV) is a hepatotrophic and lymphotrophic virus and is a global health problem. Cirrhosis and hepatocellular cancer are the most common complications of HCV. Association between HCV and B cell non-Hodgkin lymphomas (B-NHL) has been shown in epidemiological studies in the last 20 years. High prevalence of HCV infection among patients with NHL has been reported in the early 1990s by Ferri in Italy and this association has been confirmed in later studies. Geographically, HCV related NHL is highly variable and chronic rather than cleared HCV infection is required for lymphomagenesis. Although anti-HCV antibody test is the most commonly used technique in epidemiological studies, HCV-RNA is more useful test to detect the association between HCV and NHL. The optimal management of HCV related NHL is not clear. However, anti-viral treatment may be sufficient for cases with low grade and/or asymptomatic lymphomas, while immuno-chemotherapy is necessary, in spite of probable hepatic toxicity, in cases with high grade lymphomas. © 2014 Elsevier Ireland Ltd. All rights reserved.

Keywords: Lymphoma; HCV; Aggressive/indolent lymphoma; HCV prognostic score; Sustained viral response; Rituximab, Immuno-chemotherapy

1. Introduction Hepatitis C virus (HCV) is a hepatotrophic and lymphotrophic virus [1,2] HCV is a global health problem ∗

Tel.: +90 322 3386060 3142; fax: +90 322 3387320. E-mail address: [email protected]

affecting 3% of the world population and 180 million people are infected with HCV [3,4]. Cirrhosis and hepatocellular cancer are the most common complications of HCV [5]. However, HCV related health problems are not limited to the liver, hematological problems like type II mixed cryoglobulinemia (MC) or B-NHL may be seen in cases infected with HCV. In the last 20 years epidemiological studies have shown

http://dx.doi.org/10.1016/j.critrevonc.2014.10.008 1040-8428/© 2014 Elsevier Ireland Ltd. All rights reserved.

Please cite this article in press as: Paydas S. Hepatitis C virus and lymphoma. Crit Rev Oncol/Hematol (2014), http://dx.doi.org/10.1016/j.critrevonc.2014.10.008

ONCH-1893; No. of Pages 11

2

ARTICLE IN PRESS S. Paydas / Critical Reviews in Oncology/Hematology xxx (2014) xxx–xxx

a relationship between B-NHL and HCV. MC is the most commonly documented extrahepatic disorder in cases with HCV. Strong associations between HCV and MC have been shown to exist using serological and molecular techniques [6–8]. The biologic rational for an etiological relationship between HCV and B-NHL is based on epidemiological data and clinical observations [9]. High prevalence of HCV infection among patients with NHL has been reported in the early 1990s by Ferri et al. [10]. Geographically, HCV related NHL is highly variable. In a systematic review, prevalence of HCV infection has been evaluated among over 6000 cases in Europe, America and Asia. High HCV prevalence has been found especially in Southern and Eastern Europe, Japan and Southern United States. This is due to different HCV prevalence in these countries, ranging from 1–2% to more than 10% [11]. It is clear that chronic rather than cleared HCV infection is required for lymphomagenesis and chronic antigenic stimulation driven by chronic infection leads to lymphoma [12]. For this reason HCV-RNA is a more useful test to detect the association between HCV and NHL.

2. What is the most common extra-hepatic manifestation of HCV? The associatıon between HCV and NHL has been described firstly by Pozzatto and Ferri [13,14]. Large number of studies reported by Mele, Duberg and Anderson confirmed the Italian studies [15–17]. Very high prevalence of (as high as 100%) HCV has been found in type II MC [18]. Although only a minority of the HCV (+) patients show symptomatic MC, for example vasculitis, the circulating cryoglobulin reach up to 50% of the infected patients [19]. Epidemiologic studies on HCV-MC show large differences in the geographic distribution: higher prevalence in Southern Europe compared with Northern Europe or USA. It is clear that the presence of mixed cryoglobulin in HCV (+) patients may increase the risk for NHL. A thirty-five fold increased risk for NHL has been shown in HCV (+) patients with symptomatic MC in a multicenter Italian study [20]. Approximately 8–10% of patients with HCV-MC progress to overt NHL. Even after HCV eradication, HCV-MC patients may remain at increased risk to develop B-NHL [21].

3. What is risk of NHL in cases with HCV? In the last 20 years etiologic association between HCV and NHL has been reported in many studies. At the beginning in epidemiologic studies, it has been found a strong association between HCV and indolent lymphoma, but later studies have shown also increased risk for aggressive lymphoma. The most common association between HCV and NHL has been reported from Italy. In two of these studies, a three fold increased risk of low grade lymphoma has been reported [15,22]. Four fold increased risk of follicular

lymphoma has been reported from US [23]. Goldman from Egypt reported 4.4 and 3.3 fold increased risk for marginal zone lymphoma and follicular lymphoma, respectively [24]. Interestingly, a 5.2 fold increased risk of lymphoplasmacytic lymphoma has been reported from Denmark [25]. Additionally, DANVIR cohort study from Denmark showed 29.97 fold increased risk of NHL during first year of follow up [26]. Although the HCV related NHLs seem to be lower in countries with lower HCV prevalence, long-term cohort studies showed again higher prevalence of HCV related NHL in some countries. Striking geographic variation about HCV and NHL suggests that genetic and/or environmental factors are involved in the pathogenesis. For these reasons large scale studies and meta analyses have been performed and reported. However, studies showing strong associations between HCV and NHL have been included in these meta-analyses for example Italy, Egypt and Japan [24,27,28]. On the other hand there is a strict difference for HCV prevalence between Northern and Southern countries of Europe; HCV prevalence is 0.1–1%, 0.2–1.2% and 2–5% in Northern, Central and Southern Europe, respectively [9,29]. Some theories have been proposed to explain the geographic differences in the association of HCV with B-NHL: (1) Differences in the HCV carrier population with Northern European countries in which transmission is via intravenous drug use. Transmission, however, is mixed in Southern Europe: intravenous drug abuse in younger and iatrogenic transmission is more frequent in olders. (2) Long lasting infection in Southern sites may be a cause for the development of NHL. (3) There is controversy about the NHL occurrence and certain genotypes have not been included in low prevalence countries. (4) Most importantly patients with low grade lymphoma cases had longer duration of viral infection while patients with diffuse large B cell lymphoma (DLBCL) had a shorter duration of infection [3,30]. There are three meta-analyses about HCV associated NHL. First, analysis has been published in 2003 and HCVMC, 43 studies and 5542 cases have been included in this report. OR has been found to be 10.8. It has been found an association between lymphoplasmacytic lymphoma subtype and mean HCV prevalence has been found to be 13% in cases with NHL [18]. In this analysis, in 10 case-control studies, HCV prevalence has been found to be 17% and 1.5% in cases with NHL and healthy controls, respectively [31,20]. Second, meta-analysis has been published by Matsuo [32]. In this analysis 23 studies and 4049 cases and 1.813.480 controls have been included and OR has been found as 5.7. In this meta-analysis lymphoma cell type and HCV relationship has been evaluated and it has not been found an association between HCV and lymphoma subtype [32]. Third, meta-analysis has been published by Dal Maso [33]. Fifteen case-control and three prospective studies and 4678 cases

Please cite this article in press as: Paydas S. Hepatitis C virus and lymphoma. Crit Rev Oncol/Hematol (2014), http://dx.doi.org/10.1016/j.critrevonc.2014.10.008

ARTICLE IN PRESS

ONCH-1893; No. of Pages 11

S. Paydas / Critical Reviews in Oncology/Hematology xxx (2014) xxx–xxx

3

Table 1 Meta-analyses and International extranodal lymphoma consortium results about NHL risk in patients with HCV. Author

Publication year

Number of studies

Number of cases

OR for NHL

OR for NHL subtype

Reference

Gispert Matsua Dal Maso International extranodal lymphoma consortium

2003 2004 2006 2008

43 23 18 7

5542 4049 4678 4784

10.8 5.7 2.5 1.78

LPL No association No association LPL: 2.99MZL:2.47DLBCL:2.24

[18] [32] [33] [34]

Abbreviations: OR, odds ratio; NHL, non-Hodgkin lymphoma; LPL, lymphoplasmacytic lymphoma; MZL, marginal zone lymphoma; DLBCL, diffuse large B cell lymphoma.

have been included in these analysis. Relative risk has been found as 2.5 and again no difference was found between lymphoma subtypes in this report [33]. Pooled analysis of data from the International Lymphoma Epidemiology Consortium covered 7 studies and 4784 cases and indicated a 1.78 fold increased risk of NHL. HCV infection has been detected in 172 NHL cases (3.6%) and 169 controls (2.7%) and OR has been found as 2.99 for lymphoplasmacytic lymphoma, 2.47 for marginal zone lymphoma, and 2.24 for DLBCL [34]. Table 1 shows the results of the three meta-analyses and extranodal lymphoma epidemiology consortium for NHL risk in cases with HCV. In a report, subgroups of NHL have been evaluated and no clear association has been found between HCV and BNHL subtypes either indolent or aggressive [35]. However, some case-control studies showed higher risk of aggressive lymphomas compared to indolent lymphomas. Morton et al. recently published an interesting analysis. They investigated HBV, HCV and risk of NHL in solid organ transplant receivers and they found that hepatitis viral infection status at the time of transplantation was not related with NHL risk [36].

4. Which test is more useful to determine the prevalence of HCV in cases with lymphoma? An important point for different results for the association between HCV and NHL is the method used to determine the HCV infection. The detection of HCV antibodies without HCV-RNA analysis may underestimate the true rate of HCV infection in patients with NHL. This is due to the abnormal HCV antibody response both quantitatively and qualitatively in cases with NHL [37]. We performed three studies to detect the prevalence of HCV in Turkey. In our first study, anti-HCV antibody prevalence was evaluated in 228 cases with lymphoproliferative disorders. Nine of 98 cases with NHL had anti-HCV antibody and prevalence was found to be 10% [38]. In our second study, anti-HCV antibody was studied in 223 cases and we found anti-HCV positivity in 18 cases (8.1%). This prevalence was compared with donor population and OR and corrected OR were found to be 34.56 and 19.07, respectively. Additionally, HCV-RNA was studied in 67 of

these 223 samples. In this study HCV-RNA was detected in 21 of these cases (31.3%). This and some other studies suggested that HCV-RNA is more beneficial for the detection of HCV infection in these immune-suppressed cases [39–43]. In our third study, RT-PCR was used to detect the HCV-RNA both in serum and tissue samples. HCV-RNA was detected in 11 of 30 tissue samples (37%) while HCV-RNA and anti-HCV antibody were detected in only 7 (23.3%) and 3 (10%) serum samples of these 30 cases, respectively [44]. In another study considering HCV-RNA, HCV prevalence was found to be associated with diffuse large B cell lymphoma (OR: 2.19) and HCV-RNA was found to be more frequently associated with NHL than anti-HCV antibodies. This finding is related with impaired antibody production in these cases [12]. In a population based study from US, HCVRNA was found in 3.9 and 2.1% of the patients and controls, respectively and it has been found 2.46 fold increased risk for follicular lymphoma, 3.99 fold increased risk for marginal zone lymphoma and 2.04 fold increased risk for MALT lymphoma [45]. No relationship was found between anti-HCV antibodies and increased risk of NHL (OR: 2.2) in a casecontrol study from a Danish–Swedish population. Analysis restricted to HCV-RNA indicated that OR was 1.7 in this population [25]. In another Swedish study increased risk of NHL was found to be restricted to only HCV-RNA positive cases [26]. Serum samples from eight European countries, between 1998 and 2004, HCV-RNA positivity was found to be related with 1.42 fold increased risk of NHL. This was lower than the studies which HCV detected by anti-HCV antibody [12].

5. What is the route of HCV transmission? HCV is a single stranded RNA virus without DNA intermediate in its replicative cycle, so integration of HCV nucleic acid sequences into host genome seems unlikely. Therefore, it cannot be considered a typical oncogenic virus but it can exert its oncogenic potential indirectly by contributing to the modulator effects of the host immune system [46,47]. In fact, viral transmission routes are important in the development of NHL related HCV. Intravenous drug use transmission is the predominant route among

Please cite this article in press as: Paydas S. Hepatitis C virus and lymphoma. Crit Rev Oncol/Hematol (2014), http://dx.doi.org/10.1016/j.critrevonc.2014.10.008

ONCH-1893; No. of Pages 11

4

ARTICLE IN PRESS S. Paydas / Critical Reviews in Oncology/Hematology xxx (2014) xxx–xxx

Fig. 1. Pathogenesis of HCV related lymphoproliferative disorders. Reprinted from reference [56].

younger population in the Northern countries while iatrogenic transmission is important in older population in the Southern countries [48].

6. What is the pathogenetic role of HCV in NHL? It has been suggested that HCV can exert a chronic stimulus on the immune system, which facilitates the development and selection of abnormal clones and this scenario looks like the role of H Pylori for MALT lymphomas [49]. The regression of HCV related B-NHL following anti-viral treatment represents the etiologic association between HCV and lymphomas. It has been reported complete or partial responses after anti-viral therapy in HCV (+) cases but not in HCV (−) patients [9,50–52]. In early 1990s, HCV-RNA has been demonstrated in serum/plasma and liver tissues and also in peripheral blood mononuclear cells of patients with HCV [53,54]. Peripheral blood cells serve as reservoirs for persistent HCV infection. Long lasting HCV infection in B cells may cause to lymphoproliferative disorders [55]. It has been proposed that sustained antigenic stimulation of B cell compartment has a role in viral lymphotrophism [56]. Fig. 1 shows the steps for lymphomagenesis after antigenic stimulation. Viral lymphotropism has been suggested with the presence of viral replication in lymphatic cells [53]. HCV infection in bone marrow has been shown by Galli in 100% and 43% of the patients with or without MC, respectively [57]. It has been shown that HCV-E2 protein interacts with CD81

which is also present on the B cell surface. This binding is responsible for sustained polyclonal B cell activation lowering the B cell activation threshold [58,59]. Fig. 2 shows the role of connections between HCV proteins, CD81-E2, chromosomal aberrations, apoptotic inhibition, cytokines and chronic antigenic stimulation. HCV-CD81 interaction plays a central role for virus adaptation to the human host [59]. Lai used an in vitro model for HCV infection in B cell and showed the enhanced mutation rate of Ig genes [60]. The study showed the dramatically increased copy of activation induced cytidine deaminase (AID) in the B cells in HCV infected patients. HCV enhances AID expression by NFKB activation through the expression of viral core proteins. It has been found 100 fold increased levels of AID mRNA levels in CD19 (+) cells. This finding shows that HCV infects peripheral blood CD19 (+) cells and this is the reservoir during HCV infection in humans: suggesting HCV infects and may replicate in B cells [61]. These findings suggest that inappropriate expression of AID acts as a DNA mutator which enhances genetic susceptibility to mutagenesis [55]. Fig. 3 shows the role of activation induced cytidine deaminase (AID) in the B cells in HCV infected patients. This finding suggests that AID activation may be a factor in the lymphomagenic process mediated by HCV. Also significantly higher expression of several lymphomagenesis related genes have been shown in patients with HCV [19]. In transgenic mice expressing the full HCV genome in B cells was established by Tsuhiyama and 25% incidence of diffuse large B cell lymphoma within 600 days of birth was shown [62]. Oncogenic potential and lymphotrophism of different HCV genotypes are variable

Please cite this article in press as: Paydas S. Hepatitis C virus and lymphoma. Crit Rev Oncol/Hematol (2014), http://dx.doi.org/10.1016/j.critrevonc.2014.10.008

ONCH-1893; No. of Pages 11

ARTICLE IN PRESS S. Paydas / Critical Reviews in Oncology/Hematology xxx (2014) xxx–xxx

5

Fig. 2. The role of connections between HCV proteins, CD81-E2, chromosomal aberrations, apoptosis inhibition, cytokines and chronic antigenic stimulation. Reprinted from reference [56].

Fig. 3. The role of activation induced cytidine deaminase (AID) in the B cells in HCV infected patients. Reprinted from reference [55].

and results are conflicting [63–66]. Although HCV does not directly transform human B cells in vitro, transgenic mice expressing the full HCV genome in B cells spontaneously develop B cell lymphomas in vivo [67]. The most commonly investigated genetic aberration is t(14:18) and this is associated with type II or monoclonal MC. The presence of this translocation in MC has been found to be correlated with the overexpression of the anti-apoptotic Bcl-2/Bax ratio. Abnormal B cell clones following effective anti-viral treatment and in some cases a new expansion of the same clones have been shown [68]. Aneuploidy and chromosomal instability and reduced expression of retinoblastoma have been reported in HCV-infected patients [69,70]. Some cytokines and chemokines including CXCL10, CXCL13 are important in B cell trafficking and have been found to be increased in serum of MC patients [26]. High levels of B cell activator factor (BAFF or BLyS) is essential for B cell development/survival and has been found to be higher in HCV patients with lymphoproliferative disorders [71].

Recently Ng et al. looked for B cell receptors expressed by HCV associated lymphomas and interestingly they found that these lymphomas use a restricted immunoglobulin variable region gene repertoire. Also they found no evidence for their binding to the HCV antigens. With these results they suggested that most of the HCV associated lymphomas do not arise from B cells eliminating the virus [72]. It is very well known that miRNAs are important in pathogenesis of many malignant and inflammatory disorders. Among miRNAs, miR-26b has been shown to be downregulated in HCV (+) lymphomas as compared to HCV (−) splenic marginal zone lymphomas. This finding suggests a possible speculative mechanism in malignant lymphoma [45]. Additionally, in recent times it has been shown the possible contribution of NF-KB signaling and down regulation of miR-26b in the development of HCV associated B cell lymphomas in transgenic mice [73]. miRNA profile has been studied in HCV associated DLBCL in a comprehensive study and has been found decreased expression of miR-138-5p and increased expression of miR-147-a, miR-147b and miR-5115p and these alterations have been found to be poor prognostic factors in HCV related DLBCL [74]. These results suggest that miRNA profiles are related with clinical and pathological parameters and have a potential for therapeutic opportunity in HCV associated with DLBCL in near future. In summary as proposed for the last two decades, sustained HCV-driven antigenic stimulation plays a key role in inducing B cell clonal expansion and indicates a mechanism of HCV-related lymphomagenesis. Lymphatic follicles in the

Please cite this article in press as: Paydas S. Hepatitis C virus and lymphoma. Crit Rev Oncol/Hematol (2014), http://dx.doi.org/10.1016/j.critrevonc.2014.10.008

ONCH-1893; No. of Pages 11

6

ARTICLE IN PRESS S. Paydas / Critical Reviews in Oncology/Hematology xxx (2014) xxx–xxx

liver in HCV infection is the main site for B cell clonal expansion [75]. Intra-hepatic B cell clones are associated with extrahepatic manifestations of HCV. During the multi-step lymphomagenic process, chromosomal aberrations and other genetic aberrations occur [76].

7. What is the clinical/pathological/genotypic properties of HCV related NHL? It is not clear which lymphoma subtype is more prevalent in cases with HCV infection. The most frequently described subtypes are marginal zone lymphoma especially splenic marginal zone lymphoma, lymphoplasmacytic lymphoma and DLBCL [77]. Clinical data of patients with HCV related lymphoma is variable in different series. In some series more aggressive behavior, including extranodal involvement, higher LDH, and older age have been found to be increased in HCV related lymphoma, but other studies did not find such relationship [30,78–85]. Liver involvement was more common in patients with active infection and was seen in one fourth of the cases with hepatitis or cirrhosis at diagnosis. This finding suggests that active viral infection may be related with lymphomagenesis in the liver [78]. In some series, splenomegaly was found to be more frequent as compared to HCV (−) patients. The cause of this finding was portal hypertension due to impaired liver circulation in HCV infected patients. The other cause may be related with transformation from marginal zone lymphoma. An important point is the association between HCV genotypes and B-NHL. In most studies, no link has been found between specific viral genotypes and B-NHL. However, we know that this point has not been addressed in many of the studies and in some of these studies association has been evaluated more carefully [35]. Genotype II has been found to be important for the development of lymphoma [83]. In another study genotype Ib has been found to be most prevalent subtype and OR for the development of NHL has been found as 4.2 while OR was 2.9 for whole group [12]. Luppi documented an unexpectedly lower prevalence of HCV genotype 1b/3 in patients with B-NHL. In contrast the prevalence of genotypes 2a/3 and 2b/4 were found to be higher in B-NHL [84]. These findings suggest that some HCV genotypes are more lymphomagenic. Another interesting point is the duration of HCV infection and subtype of lymphoma. Pallicelli reported a higher prevalence of genotype 1 and shorter duration of HCV infection in cases with DLBCL as compared to higher prevalence of genotype 2 and longer duration of HCV infection in patients with indolent-low grade lymphoma. It is known that HCV genotype 2 is related with longer duration of viral infection. It has been speculated that it may induce a persistent chronic immune-stimulation of B cells over time. In contrast, direct lymphocyte transformation for HCV genotype 1 in aggressive lymphomas may occur on the basis of the shorter duration of viral exposure [79].

8. Anti-viral treatment for HCV associated NHL: when and whom? Anti-viral treatment (AVT) has been found to be effective in low grade lymphomas. Interestingly HCV infected patients treated by interferon and achieved sustained viral response (SVR) had a lower rate of lymphoma than who had not received AVT. This finding suggests that AVT may be preventive for lymphomagenesis in HCV infected patients. New anti-viral drugs may be attractive at this situation [85,86,87,88]. Subcutaneous pegylated intereferon alpha 2a, 180 ␮g weekly plus oral ribavirin (800, 1000 and 1200 mg daily dose have been recommended for patients <65 kg, 65–85 kg and >85 kg, respectively) is the therapy of choice in these cases. Erythropoietin alpha 2a 40.000 IU weekly subcutaneously has been added in cases if hemoglobin level decreased by more than 2 g. Duration of treatment has been recommended as 1 year in patients HCV genotype 1 or 4, and 6 months for patients genotype 2 or 3. Definition of response to anti-viral treatment is important: SVR has been defined as HCV RNA negativity (<12 IU/ml) 24 weeks after stopping therapy. If HCV RNA is positive after 3 months from the beginning of AVT this has been accepted as nonrespondance. In this study response rate been found as 71% as SVR [30]. Lymphoma regression has been found to be correlated with reduction of viral load [9]. This approach is valid for asymptomatic indolent lymphomas. A systematic review showed that complete responses were achieved in 75% of the HCV (+) cases [89]. There is no prospective study about the efficacy of AVT in cases with HCV related NHL. Arcaini et al. recently reported updated results of Fundazione Italiana Linfomi. They followed 704 HCV (+) cases with indolent NHL between 1993 and 2009 in 39 centers. Among these cases, 134 were managed with AVT. For entire cohort 5 year overall survival (OS) and progression free survival (PFS) were found to be 78% and 48%, respectively. In multivariate analysis the use of AVT during the patients’ life had positive impact on OS. With the use of AVT, HR was 0.21 and 0.80 for OS and PFS, respectively. Overall response rate was 77% with 44% complete response. HCV-RNA clearance was detected in 80% of the cases and this was found to be associated with lymphoma regression. This is the largest study focused on anti-lymphoma efficacy of AVT in HCV (+) indolent lymphoma [90].

9. Management of DLBCL associated with HCV HCV eradication is not the only option for aggressive lymphomas and/or symptomatic indolent lymphomas. These patients require rituximab containing chemotherapy (CT) [30]. It has been reported that CT is tolerated relatively well. Treatment must be given for cure intent. Higher complete response and event-free survival have been reported in some series [79]. However in some cases, CT cannot be given

Please cite this article in press as: Paydas S. Hepatitis C virus and lymphoma. Crit Rev Oncol/Hematol (2014), http://dx.doi.org/10.1016/j.critrevonc.2014.10.008

ONCH-1893; No. of Pages 11

ARTICLE IN PRESS S. Paydas / Critical Reviews in Oncology/Hematology xxx (2014) xxx–xxx

due to impaired liver function [78]. AVT for the eradication of HCV may be an option after successful lymphoma therapy [35]. La mura et al. retrospectively analyzed a study and found that PFS and OS were slightly longer in patients receiving anti-virals after immuno-chemotherapy. SVR was obtained in 32% of the HCV (+) cases receiving anti-viral therapy. None of the patients who eradicated HCV infection had relapse while one third of the cases who did not respond to anti-viral treatment showed relapse [91]. Similar outcome for aggressive lymphomas has been reported in Japan [92].

10. Potential benefits/harms of rituximab and anti-viral using in cases with HCV associated NHL The addition of rituximab to chemotherapy is considered as the greatest advance in the treatment of B-NHL in the past two decades. However it is not clear the benefit of rituximab in cases with HCV associated NHL due to potential increase in hepatic toxicity and we need to know the early and late toxicity of rituximab using in these cases and one of the most critical points in these cases is the safety of rituximab using in addition to the efficacy. It is believed that in contrast to HBV infection, rituximab is well tolerated in cases with HCV [35,78]. However HCV reactivation in patients receiving immuno-chemotherapy (ICT) is not clear as observed in HBV reactivation in HBV infected cases [9]. HCV-RNA levels increase during I-CT as a result of viral reactivation, but HCV-RNA decrease within 6 months, generally without major clinical problem [93]. However, there is possibility of liver toxicity due to either direct cytotoxicity or increased drug toxicity from suboptimal drug metabolism. These are important points and it has been reported higher toxic deaths in HCV (+) cases. This may be due to withdrawal of chemotherapy or reduction of steroids, indicating an immune mediated mechanism of liver damage [81,87,93]. For this reason monitoring of liver function tests and viral load must be performed carefully and also if necessary modification of the treatment must be done [35,82]. If there is no liver dysfunction at the beginning HCV (+), patients faired similarly with HCV (−) patients after I-CT [93,94]. Anti-viral prophylaxis has not shown to provide a protective effect to suppress HCV replication while patients receiving chemotherapy [9,93]. We need prospective controlled trials to determine this controversial issue. Whether HCV eradication after I-CT may impact survival outcome is not clear [9]. HBV co-infection, advanced stage disease and nodal origin are the strongest adverse prognostic indicators [78]. These and additional risk factors must be determined to decrease the risk of hepatic toxicity. An important question has not been answered: is it necessary to give concomitant ribavirin or interferon while patient receiving anti-neoplastic treatment or anti-virals must be given after the end of treatment? Further studies are needed to answer this question. The benefits and risks of using rituximab in cases with HCV related NHL is not clear and available results are

7

conflicting. An important large retrospective multicentric study has been reported from Italy in the last year. In this study, 535 consecutive cases with HCV associated DLBCL treated by anthracycline based CT have been evaluated. Severe hepatotoxicity has been observed in 14% of the cases and it has not been found an association between using rituximab and hepatotoxicity. Three factors have been found to be significant in multivariate analysis: ECOG performance status ≥2, serum albumin <3.5 g/dl, HCV viral load >1000 KIU/ml. At the end authors suggested a new prognostic score named HCV prognostic score: low = 0, intermediate = 1, high ≥2. This score was found to be better than international prognostic score. This new prognostic score retained prognostic value in the subgroup of patients treated with and without rituximab [95]. This is an important result but we need more absolute results, especially prospective randomized studies compating I-CT and CT in these cases. In a retrospective analysis from GELA studies (LNH 93 and LNH98) the outcome of the patients with HCV has been found to be poor. The short term hepatic toxicity has been found to be strongly increased and has been found in 15 of the 23 cases [81]. In another retrospective study, 160 HCV (+) NHL patients (101 aggressive and 59 indolent lymphomas) have been evaluated for rituximab using. Hepatic toxicity was reported in 18% of the cases receiving I-CT (this was 7% in cases receiving chemotherapy only) and median PFS was found to be significantly shorter in cases requiring interruption of chemotherapy due to hepatic toxicity. With this study authors suggested a limitation but not absolute contraindication for the use of rituximab in cases with HCV infection [96]. Hepatic toxicity associated with rituximab has been evaluated retrospectively in another study by Marignani et al. in cases with B-NHL. Hepatic toxicity has been reported in 3 of 9 cases with HCV (+) NHL while none of the 95 cases with HCV (−). Although HCV flares were found to be significant risk factor in HCV patients receiving rituximab there was no difference in 12 months follow up [97]. In large study from 3 centers in Northern Italy, 132 of 156 consecutive HCV (+) DLBCL cases followed between 1994 and 2004 were treated with curative intent. The addition of rituximab was not found to be associated with decreased tolerance to chemotherapy; increase in liver enzyme levels (grade I) was detected in only 5 of 35 cases (14%) treated with rituximab containing regimen [78]. Nishikawa et al. from Japan retrospectively analyzed 248 patients with DLBCL treated between 2004 and 2011; 220 of these cases were HCV (−) and 28 were HCV (+). In terms of OS and PFS, there were no significant differences according to the HCV status. Although hepatic toxicity was found in 25% and 15.9% of the cases with HCV (+) and (−) cases, respectively, none of the cases discontinued treatment due to hepatic toxicity [98]. Recently Zaky et al. analyzed 137 cases with HCV (+) DLBCL and compared the outcome of the patients treated with chemotherapy with or without rituximab. They found significantly increased hepatic toxicity (28% vs 18%) receiving rituximab and worse outcome for PFS and OS [99]. However all of these studies are

Please cite this article in press as: Paydas S. Hepatitis C virus and lymphoma. Crit Rev Oncol/Hematol (2014), http://dx.doi.org/10.1016/j.critrevonc.2014.10.008

Study years

N (evaluated

(+) Salah-Eldin [100]

Prospective

2008–2013

280 DLBCL: 280

280

Marignani [97]

Retrospective

2004–2006

104 DLBCL: 56 FL: 56 SLL: 11 MCL: 6 Other: 3 132 DLBCL: 132

9

Visco [78]

Retrospective

1994–2004

Nishikawa [98]

Retrospective

2004–2011

Merli [95]

Retrospective

1995–2010

Zaky [99]

Retrospective

Besson [81]

Retrospective

LNH-93 LNH-98

HCV

Rituximab

Hepatic toxicity (Grade III–IV)

(−)

(+)

(−)

R(+)

0

200

80

53/200 (26.5%)

95

104

0

3/9: HCV (+)

Median follow up (month)

General comment for HT

43

41

NA

–

NA

Pretreatment liver dysfunction important Despite increase in LFT, no major clinical limitation

NA

NA

NA

12

–

66%a HCV (+) 77% HCV (−) 70%b

–

36

60%b

24

PFS (months)

OS (months)

R (−)

R (+)

R(−)

R(+)

R(−)

11/80 (13.75%)

40

35

51

0

NA

–

5/35 0 (14%) Grade I 7/28: HCV (+) 0 35/220 HCV (−)

NA

45%b

80%

0/95: HCV (−)

132

0

248 DLBCL: 248

28

535 DLBCL: 535

35

97

220

248

0

535

0

255

280

137 DLBCL: 137

137

0

Among 5586 DLBCL

26

72

NA

NA

16%

14%

64%a HCV (+) 65% HCV (−) 55%b

28%

18%

55%

65% (15/23)

24

R did not affect tolerance No patient required discontinuation I-CT

HCV prognostic score important High incidence of HT with Rituximab 2 year OS-PFS 56%-53% HCV (+) vs 80%-74% HCV (−)

Abbreviations: DLBCL, diffuse large B cell lymphoma; NHL, non-Hodgkin lymphoma; R, rituximab; PFS, progression free survival; OS, overall survival; I-CT, immuno-chemotherapy; HT, hepatotoxicity. a 3 years PFS and OS NS. b 4 years PFS(Sig) OS (NS).

ARTICLE IN PRESS

Study type

S. Paydas / Critical Reviews in Oncology/Hematology xxx (2014) xxx–xxx

Author (Reference)

ONCH-1893; No. of Pages 11

8

Please cite this article in press as: Paydas S. Hepatitis C virus and lymphoma. Crit Rev Oncol/Hematol (2014), http://dx.doi.org/10.1016/j.critrevonc.2014.10.008

Table 2 Hepatic toxicity in cases with B cell lymphoma treated with or without rituximab containing regimens.

ONCH-1893; No. of Pages 11

ARTICLE IN PRESS S. Paydas / Critical Reviews in Oncology/Hematology xxx (2014) xxx–xxx

retrospective, sample sizes are relatively small and rituximab using is not balanced in study groups and also late complications associated with rituximab in these cases are not clear due to the limited time of follow ups. The only prospective study from Egypt found no significant difference for PFS and OS according to the rituximab administration. This study was carried out on 280 HCV (+) cases with DLBCL; 200 of them received I-CT while 80 cases received CT only. Rituximab using caused severe hepatic toxicity in 26.5% of the cases although severe hepatotoxicity developed in 13.75% of the cases not receiving rituximab. In this study patients with HCV associated DLBCL have no benefit from addition of rituximab to chemotherapy [100]. Table 2 shows the studies evaluating hepatic toxicity with rituximab using in cases with HCV related NHL. In summary rituximab is an important monoclonal antibody in the management of cases with DLBCL. However close monitoring of liver function tests and viral load, especially in cases with abnormal liver function tests at the beginning, necessary.

11. Conclusion HCV is a global health problem affecting 180 million people. Higher HCV prevalence has been found in Southern and Eastern Europe, Japan and Southern United States and Egypt. This is associated with HCV prevalence, ranging from 1 to 2% to more than 10%. The detection of HCV antibodies without HCV-RNA analysis in serum or tissue samples may underestimate the true rate of HCV infection. Three factors have been found to be significant in multivariate analysis: ECOG performance status ≥2, serum albumin <3.5 g/dl, HCV viral load >1000 KIU/ml and a new prognostic score has been suggested for these cases. Anti-viral treatment is the treatment of choice in cases with low grade lymphoma while immuno-chemotherapy is necessary in cases with aggressive lymphomas.

Reviewers Dr. Pellegrino Musto, Head, IRCCS Centro Riferimento Oncologico Basilicata, Onco-Hematology, Via Padre Pio, 1, I-85028 Rionero in Vulture, PZ, Italy. Dr. Luca Arcaini, Assistant professor, Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Department of Molecular Medicine, University of Pavia, Pavia, Italy, Viale Golgi 19 Pavia, Italy. Dr. Pier Luigi Zinzani, M.D., Ph.D., University of Bologna, Institute of Hematology and Medical Oncology, via Massarenti, 9, I-40138 Bologna, BO, Italy.

9

References [1] Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335–74. [2] Durand T, Di Liberto G, Colman H, et al. Occult infection of peripheral B cells by hepatitis C variants which have low translational efficiency in cultured hepatocytes. Gut 2010;59:934–42. [3] Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S. Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. J Hepatol 2013;59: 169–77. [4] Zignego AL, Giannini C, Ferri C. Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol 2007;13:2467–78. [5] Simonetti RG, Camma C, Fiorello F, et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med 1992;116:97–102. [6] Misiani R, Bellavita P, Fenili D, et al. Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med 1992;117:573–7. [7] Ferri C, Greco F, Longombardo G, et al. Association between hepatitis C virus and mixed cryoglobulinemia. Clin Exp Rheumatol 1991;9:621–4. [8] Zignego AL, Ferri C, Giannini C, et al. Hepatitis C virus infection in mixed cryoglobulinemia and B-cell non-Hodgkin’s lymphoma: evidence for a pathogenetic role. Arch Virol 1997;142:545–55. [9] Hartridge-Lambert SK, Stein EM, Markowitz AJ, Portlock CS. Hepatitis C and non-Hodgkin lymphoma: the clinical perspective. Hepatology 2012;55:634–41. [10] Ferri C, La Civita L, Caracciolo F, Zignego AL. Non-Hodgkin’s lymphoma: possible role of hepatitis C virus. JAMA 1994;272:355–6. [11] Negri E, Little D, Boicchi M, Vecchia CLA, Franceschi S. B-cell nonHodgkin’s lymphoma hepatitis C virus infection: a systematic review. Int Cancer J 2004;111:1–8. [12] Nieters A, Kallinowski B, Brennan P, et al. Hepatitis C and risk of lymphoma: results of the European multicenter case-control study EPILYMPH. Gastroenterology 2006;131:1879–86. [13] Pozzato G, Mazzaro C, Crovatto M, et al. Lowgrade malignant lymphoma, hepatitis C virus infection, and mixed cryoglobulinemia. Blood 1994;84:3047–53. [14] Ferri C, Caracciolo F, Zignego AL, et al. Hepatitis C virus infection in patients with non-Hodgkin’s lymphoma. Br J Haematol 1994;88:392–4. [15] Mele A, Pulsoni A, Bianco E, et al. Hepatitis C virus and B-cell nonHodgkin lymphomas: an Italian multicenter case-control study. Blood 2003;102:996–9. [16] Duberg A-S, Nordstrom M, Torner A, et al. Non-Hodgkin’s lymphoma and other nonhepatic malignancies in Swedish patients with hepatitis C virus infection. Hepatology 2005;41:652–9. [17] Anderson LA, Pfeiffer R, Warren JL, et al. Hematopoietic malignancies associated with viral and alcoholic hepatitis. Cancer Epidemiol Biomarkers Prev 2008;17:3069–75. [18] Gisbert JP, García-Buey L, Pajares JM, Moreno-Otero R. Prevalence of hepatitis C virus infection in B-cell non-Hodgkin’s lymphoma: systematic review and meta-analysis. Gastroenterology 2003;125:1723–32. [19] Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol 2002;55:4–13. [20] Monti G, Pioltelli P, Saccardo F, et al. Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias. Arch Intern Med 2005;165:101–5. [21] Landau DA, Saadoun D, Halfon P, et al. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 2008;58:604–11.

Please cite this article in press as: Paydas S. Hepatitis C virus and lymphoma. Crit Rev Oncol/Hematol (2014), http://dx.doi.org/10.1016/j.critrevonc.2014.10.008

ONCH-1893; No. of Pages 11

10

ARTICLE IN PRESS S. Paydas / Critical Reviews in Oncology/Hematology xxx (2014) xxx–xxx

[22] Talamini R, Montella M, Crovatto M, et al. Non-Hodgkin’s lymphoma and hepatitis C virus: a case-control study from northern and southern Italy. Int J Cancer 2004;110:380–5. [23] Morton LM, Engels EA, Holford TR, et al. Hepatitis C virus and risk of non-Hodgkin lymphoma: a population-based case-control study among Connecticut women. Cancer Epidemiol Biomarkers Prev 2004;13:425–30. [24] Goldman L, Ezzat S, Mokhtar N, et al. Viral and non-viral risk factors for non-Hodgkin’s lymphoma in Egypt: heterogeneity by histological and immunological subtypes. Cancer Causes Control 2009;20: 981–7. [25] SchD ollkopf C, Smedby KE, Hjalgrim H, et al. Hepatitis C infection and risk of malignant lymphoma. Int J Cancer 2008;122: 1885–90. [26] Omland LH, Jepsen P, Krarup H, et al. Liver cancer and non-Hodgkin lymphoma in hepatitis C virus-infected patients: results from the DANVIR cohort study. Int J Cancer 2012;130:2310–7. [27] Cocco P, Piras G, Monne M, et al. Risk of malignant lymphoma following viral hepatitis infection. Int J Hematol 2008;87: 474–83. [28] Mizorogi F, Hiramoto J, Nozato A, et al. Hepatitis C virus infection in patients with B-cell non-Hodgkin’s lymphoma. Intern Med 2000;39:112–7. [29] Sy T, Jamal MM. Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:41–6. [30] Pellicelli AM, Marignani M, Zoli V, et al. Hepatitis C virus-related B cell subtypes in non Hodgkin’s lymphoma. World J Hepatol 2011;3(11):278–84. [31] Franzin F, Efremov DG, Pozzato G, Tulissi P, Batista F, Burrone OR. Clonal B-cell expansions in peripheral blood of HCV infected patients. Br J Haematol 1995;90:548–52. [32] Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin’s lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 2004;95:745–52. [33] Dal Maso L, Franceschi S. Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2006;15:2078–85. [34] de Sanjose S, Benavente Y, Vajdic CM, et al. Hepatitis C and nonHodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008;6:451–8. [35] Forghieri F, Luppi M, Barozzi P, et al. Pathogenetic mechanisms of hepatitis C virus-induced B-cell lymphomagenesis. Clin Dev Immunol 2012:1–9 [Article ID 807351]. [36] Morton LM, Gibson TM, Clarke CA, Lynch CF, Weisenburger DD, Engels EA. Hepatitis B or C virus infection and risk of non-Hodgkin lymphoma among solid organ transplant recipients. Haematologica 2014;99:70–3. [37] Mazzaro C, Zagonel V, Monfardini S, et al. Hepatitis C virus and non-Hodgkin’s lymphomas. Br J Haematol 1996;94: 544–50. [38] Paydas S, Kilic¸ B, Sahin B, Bugdayci R. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders in Southern Turkey. Br J Cancer 1999;80:1303–5. [39] Paydas S, Kilic B, Yavuz S, et al. Anti-HCV and HCV-RNA prevalence and clinical correlations in cases with non-Hodgkin’s lymphoma. Am J Hematol 2003;74:89–93. [40] Greeve J, Philipsen A, Krause K, et al. Expression of activationinduced cytidine deaminase in human B-cell non-Hodgkin lymphomas. Blood 2003;101:3574–80. [41] Agematsu K, Hokibara S, Nagumo H, Komiyama A. CD27: a memory B-cell marker. Immunol Today 2000;21:204–6. [42] Mizuochi T, Ito M, Saito K, et al. Possible recruitment of peripheral blood CXCR3+ CD27+ CD19+ B cells to the liver of chronic hepatitis C patients. J Interferon Cytokine Res 2010;30:243–52.

[43] Pal S, Sullivan DG, Kim S, et al. Productive replication of hepatitis C virus in perihepatic lymph nodes in vivo: implications of HCV lymphotropism. Gastroenterology 2006;130:1107–16. [44] Paydas S, Ergin M, Tanriverdi K, et al. Detection of hepatitis C virus RNA in paraffin-embedded tissues from patients with non-Hodgkin’s lymphoma. Am J Hematol 2004;76:252–7. [45] Engels EA, Chatterjee N, Cerhan JR, et al. Hepatitis C virus infection and non-Hodgkin lymphoma: results of the NCI-SEER multi-center case-control study. Int J Cancer 2004;111:76–80. [46] Ferri C, La Civita L, Zignego AL, Pasero G. Viruses and cancers: possible role of hepatitis C virus. Eur J Clin Invest 1997;27:711–8. [47] Silvestri F, Baccarani M. Hepatitis C virus-related lymphomas. Br J Haematol 1997;99:475–80. [48] Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol 2008;48:148–62. [49] Stolte M, Bayerdorffer E, Morgner A, et al. Helicobacter and gastric MALT lymphoma. Gut 2002;50(Suppl. 3):19–24. [50] Hermine O, Lefrère F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89–94. [51] Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell nonHodgkin’s lymphoma: a multicenter Italian experience. J Clin Oncol 2005;23:468–73. [52] Arcaini L, Vallisa D, Merli M. Hematological response to antiviral therapy in 94 patients with indolent B-cell lymphomas associated with hepatitis C virus infection: a study of the Fondazione Italiana Linfomi (FIL). Ann Oncol 2011;22:128–9 [Lugano Meeting Abstract no. 138]. [53] Zignego AL, Macchia D, Monti M, et al. Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepat 1992;15:382–6. [54] Ferri C, Monti M, La Civita L, et al. Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood 1993;82:3701–4. [55] Ito M, Kusunoki H, Mochida K, Yamaguchi K, Mizuochi T. HCV infection and B-cell lymphomagenesis. Adv Hemat 2011:1–8. ID 835314. [56] Zignego AL, Giannini C, Gragnani L. HCV and lymphoproliferation. Clin Dev Immunol 2012:1–8. ID 980942. [57] Galli M, Zehender G, Monti G, et al. Hepatitis C virus RNA in the bone marrow of patients with mixed cryoglobulinemia and in subjects with noncryoglobulinemic chronic hepatitis type C. J Infect Dis 1995;171:672–5. [58] Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 1998;282:938–41. [59] Rosa D, Saletti G, De Gregorio E, et al. Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. PNAS 2005;102: 18544–9. [60] Machida K, Cheng KT, Sung VM, et al. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci 2004;101:4262–7. [61] Ito M, Murakami K, Suzuki T, et al. Enhanced expression of lymphomagenesis-related genes in peripheral blood B cells of chronic hepatitis C patients. Clin Immunol 2010;135:459–65. [62] Tsukiyama-Kohara K, Sekiguchi S, Kasama Y, Salem NE, Machida K, Kohara M. Hepatitis C virus-related lymphomagenesis in a mouse model. ISRN Hematol 2011:1–8 [Article ID 167501]. [63] Silvestri F, Barillari G, Fanin R, et al. The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin’s lymphoma. Leukemia 1997;11:2157–61. [64] Luppi M, Grazia Ferrari M, Bonaccorsi G, et al. Hepatitis C virus infection in subsets of neoplastic lymphoproliferations not associated with cryoglobulinemia. Leukemia 1996;10:351–5. [65] De Rosa G, Gobbo ML, De Renzo A, et al. High prevalence of hepatitis C virus infection in patients with B-cell lymphoproliferative disorders in Italy. Am J Hematol 1997;55:77–82.

Please cite this article in press as: Paydas S. Hepatitis C virus and lymphoma. Crit Rev Oncol/Hematol (2014), http://dx.doi.org/10.1016/j.critrevonc.2014.10.008

ONCH-1893; No. of Pages 11

ARTICLE IN PRESS S. Paydas / Critical Reviews in Oncology/Hematology xxx (2014) xxx–xxx

[66] Pioltelli P, Gargantini L, Cassi E, et al. Hepatitis C virus in nonHodgkin’s lymphoma. A reappraisal after a prospective case-control study of 300 patients. Lombart Study Group of HCV-Lymphoma. Am J Hematol 2000;64:95–100. [67] Kasama Y, Sekiguchi S, Saito M, et al. Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo. Blood 2010;116: 4926–33. [68] Giannelli F, Moscarella S, Giannini C, et al. Effect of antiviral treatment in patients with chronic HCV infection and t(14;18) translocation. Blood 2003;102:1196–201. [69] Goldberg-Bittman L, Kitay-Cohen L, Hadari R, Yukla M, Fejgin MD, Amiel A. Random aneuploidy in chronic hepatitis C patients. Cancer Genet Cytogenet 2008;180:20–3. [70] Machida K, Liu JC, McNamara G, Levine A, Duan L, Lai MMC. Hepatitis C virus causes uncoupling of mitotic checkpoint and chromosomal polyploidy through the Rb pathway. J Virol 2009;83:12590–600. [71] De Vita S, Quartuccio L, Fabris M. Hepatitis C virus infection, mixed cryoglobulinemia and BLyS upregulation: targeting the infectious trigger, the autoimmune response, or both? Autoimmun Rev 2008;8:95–9. [72] Ng PP, Kuo CC, Wang S, et al. B-cell receptors expressed by lymphomas of hepatitis C virus (HCV)-infected patients rarely react with the viral proteins. Blood 2014;123:1512–5. [73] Kasama Y, Mizukami T, Kusunoki H, et al. B-cell-intrinsic hepatitis C virus expression leads to B-cell-lymphomagenesis and induction of NF-Kb signalling. PLOS ONE 2014;9:1–11. [74] Augello C, Gianelli U, Savi F, et al. MicroRNA as potential biomarker in HCV-associated diffuse large B-cell lymphoma. J Clin Pathol 2014;67:697–701. [75] Sansonno D, De Vita S, Iacobelli AR, Cornacchiulo V, Boiocchi M, Dammacco F. Clonal analysis of intrahepatic B cells from HCV-infected patients with and without mixed cryoglobulinemia. J Immunol 1998;160:3594–601. [76] Sansonno D, Lauletta G, De Re V, et al. Intrahepatic B cell clonal expansions and extrahepatic manifestations of chronic HCV infection. Eur J Immunol 2004;34:126–36. [77] Libra M, Polesel J, Russo AE, et al. Extrahepatic disorders of HCV infection: a distinct entity of B-cell neoplasia? Int J Oncol 2010;36:1331–40. [78] Visco C, Arcaini L, Brusamolino E, et al. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol 2006;17:1434–40. [79] Park BB, Kim JS, Lee YY, et al. Clinical characteristics and outcome for hepatitis C virus-positive diffuse large B-cell lymphoma. Leuk Lymphoma 2008;49:88–94. [80] Strianese D, Tranfa F, Finelli M, et al. Hepatitis C virus infection in ocular adnexal lymphomas. Arch Ophthalmol 2010;128:1295–9. [81] Besson C, Canioni D, Lepage E, et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C viruspositive patients in LNH 93 and LNH 98 groupe d’etude des lymphomes de l’adulte programs. J Clin Oncol 2006;24:953–60. [82] Ennishi D, Maeda Y, Niitsu N, et al. Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood 2010;116:5119–25. [83] Torres HA, Nevah MI, Barnett BJ, et al. Hepatitis C virus genotype distribution varies by underlying disease status among patients in the

[84] [85]

[86]

[87]

[88]

[89]

[90]

[91]

[92]

[93]

[94]

[95]

[96]

[97]

[98]

[99]

[100]

11

same geographic region: a retrospective multicenter study. J Clin Virol 2012;54(3):218–22. Luppi M, Ferrari MG, Torelli G. Hepatitis C virus genotype distribution in B-cell non-Hodgkin lymphoma. Ann Int Med 1998;128:602. Kawamura Y, Ikeda K, Arase Y, et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med 2007;120:1034–41. Poordad F, McCone Jr J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195–206. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405–16. Pawlotsky J. The results of phase III clinical trials with telaprevir and boceprevir presented at the liver meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology 2011;140:746–54. Gisbert JP, Garc´ıa-Buey L, Pajares JM, Moreno-Otero R. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Alim Pharmacol Ther 2005;21:653–62. Arcaini L, Vallisa D, Rattotti S, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. Ann Oncol 2014;25:1404–10. La Mura V, De Renzo A, Perna F, et al. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive nonHodgkin’s lymphoma. J Hepatol 2008;49:557–63. Tomita N, Kodama F, Takabayashi M, et al. Clinical features and outcome in HCV-positive aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 2003;44:1159–64. Nooka A, Shenoy PJ, Sinha R, Lonial S, Flowers CR. Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature. Clin Lymphoma Myeloma Leukemia 2011;11:379–84. Cox MC, Aloe-Spiriti MA, Cavalieri E. HCV infection, B-cell nonHodgkin’s lymphoma and immunochemotherapy: evidence and open questions. World J Gastrointest Oncol 2012;15:46–53. Merli M, Visco C, Spina M, et al. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica 2013;99:489–96. Arcaini L, Merli M, Passamonti F, et al. Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin’s lymphomas. Am J Hematol 2010;85:46–50. Marignani M, Mangone M, Cox MC, et al. HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin’s lymphoma treated with rituximab-containing regimens. Dig Liver Dis 2011;43:139–42. Nishikawa H, Tsudo M, Osaki Y. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience. Oncol Rep 2012;28:835–40. Zaky AH, Bakry R, El-Sayed MI, Elwanis MA, Nabih O. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era. Hematology 2014:20 [Epub ahead of print]. Salah-Eldin MA, Ebrahim MA, El-Sadda W. Clinical outcome of HCV-positive patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy. Ann Hematol 2014 [published online 21 June].

Please cite this article in press as: Paydas S. Hepatitis C virus and lymphoma. Crit Rev Oncol/Hematol (2014), http://dx.doi.org/10.1016/j.critrevonc.2014.10.008